Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Portfolio Pulse from Vandana Singh
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) announced that its Phase 3 HELIOS-B study of vutrisiran for ATTR amyloidosis with cardiomyopathy (ATTR-CM) met its primary and secondary endpoints, showing significant reductions in mortality and cardiovascular events. The company plans to proceed with global regulatory submissions.

June 24, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals' Phase 3 HELIOS-B study of vutrisiran met its primary and secondary endpoints, showing significant reductions in mortality and cardiovascular events. The company plans to proceed with global regulatory submissions, leading to a 29.2% surge in share price.
The successful Phase 3 trial results for vutrisiran, showing significant reductions in mortality and cardiovascular events, are highly positive for Alnylam. The company's plan to proceed with global regulatory submissions further boosts investor confidence, leading to a significant surge in share price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100